everyone deserves to see the world clearly
through healthy eyes
Our Mission
At Dopavision, we’re bringing a new perspective to the world of eye care. Our approach combines selective ocular light stimulation with easily accessible consumer electronics. By non-invasively engaging the eye’s innate signalling pathways, our goal is to address a significant global public health issue and empower as many people as possible to build a healthier, brighter future.
MyopiaX® Clinical Trial
MyopiaX® is our transformative approach that aims to slow the progression of myopia (nearsightedness) in children and adolescents. It administers our patented, first-in-class selective ocular light stimulation to the eye’s blind spot, non-invasively engaging the innate mechanisms regulating eye growth. By using consumer electronics, MyopiaX® aims to offer an interactive, child-friendly approach, designed to integrate seamlessly into daily routines.
MyopiaX® is currently being investigated in a multicentre, randomized, controlled clinical trial (NCT04967287) to evaluate its safety, tolerability, and signals of clinical effect on the progression of myopia in children. The MyopiaX-1 proof-of-concept trial is an important step towards our mission of providing a safe, non-invasive therapeutic alternative to slow the progression of myopia.
The Global Myopia Crisis
Myopia, or nearsightedness, is a rapidly growing public health issue that is projected to impact nearly 50% of the global population by 2050. Progressive myopia is marked by a worsening ability to see distant objects clearly, often due to the continuous elongation of the eyeball, causing images to focus in front of the retina. Without proper intervention, this condition can significantly increase the risk of developing serious sight-threatening conditions later in life.
Targeting the slowing of myopia progression in children and adolescents is currently the most effective strategy to mitigate the risk of long-term eye health complications. With MyopiaX®, we aim to enrich the myopia control portfolio, providing millions of children worldwide with a safe, non-invasive therapeutic approach.
Our Product
Our lead product is MyopiaX®, a breakthrough technology targeted at children and young adolescents. It has the potential to become the first digital therapy to control childhood myopia, leveraging our patented, light-based technology that stimulates specific photosensitive cells in the retina.
MyopiaX® is designed to achieve a medical effect while children play exciting games or use educational digital content. It runs on standard digital devices and is easy to use for children under minimal supervision of their parents. A clinical investigation evaluating the efficacy of MyopiaX® is currently underway.
Our Partners
Dopavision is funded as part of the BMBF’s Industry-in-Clinic Platform Program (FKZ: 13GW0625)